Literature DB >> 19665810

Quality outcomes of ACHD patients undergoing cardiovascular procedures and hospital admissions in a free-standing children's hospital.

Stephen R Crumb1, Stephen C Cook, John P Cheatham, Mark Galantowicz, Timothy F Feltes, Alistair Phillips, David P Chan, Ralf J Holzer, Matt Sisk, Vince Olshove, Lindsey R Cook, Jenne C Hickey, Sharon L Hill, Curt J Daniels.   

Abstract

OBJECTIVES: Describe quality outcomes of adults with congenital heart disease (ACHD) undergoing cardiovascular procedures and admissions in a free-standing children's hospital with a multi-disciplinary ACHD program and compared with pediatric outcomes.
BACKGROUND: A challenge for the U.S. healthcare system is where to treat the >1 million ACHD patients (pts): adult hospitals without CHD care, or pediatric hospitals without adult services.
METHODS: We reviewed all CHD pts ≥ 18 yrs of age from 2002-2007. Procedural and hospital related morbidity and mortality were recorded. ANOVA and t-test compared adult with pediatric pts.
RESULTS: Overall, 782 pts, mean age of 29.8 ± 9.9 yrs, encountered 1490 procedures/admissions. For 178 cardiac surgeries (72% reoperations), mortality was 1.8% and complication rate was 7.3%. There was 0% mortality for 412 cardiac catheterizations, 311 electrophysiological procedures, 401 transesophageal echocardiograms (TEE), 244 exercise tests (ETT) and 54 medical admissions. Major adverse event rate was 0.6% for cardiac catheterization and electrophysiological procedures. No adverse events occurred during TEE and ETT. Only 4 pts required transfer to an adult institution (0.25%). There was no significant difference in mortality or adverse events between pediatric and adult CHD pts, p>0.05.
CONCLUSIONS: The optimal setting to provide ACHD care remains a complex issue. Our study is the first to demonstrate 1) a low incidence of morbidity and mortality for ACHD pts undergoing cardiovascular procedures or admissions at a free-standing children's hospital, 2) outcomes comparable to pediatric CHD pts. Future models incorporating ACHD programs within pediatric heart centers should be considered to care for this complex population.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19665810     DOI: 10.1016/j.ijcard.2009.07.007

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Outcomes in adult congenital heart surgery: analysis of the Society of Thoracic Surgeons database.

Authors:  Christopher E Mascio; Sara K Pasquali; Jeffrey P Jacobs; Marshall L Jacobs; Erle H Austin
Journal:  J Thorac Cardiovasc Surg       Date:  2011-09-10       Impact factor: 5.209

2.  Overview of adult congenital heart transplants.

Authors:  Roosevelt Bryant; David Morales
Journal:  Ann Cardiothorac Surg       Date:  2018-01

3.  Sleep-Disordered Breathing is Associated With Increased Mortality in Hospitalized Infants With Congenital Heart Disease.

Authors:  Daniel Combs; Grant Skrepnek; Michael D Seckeler; Brent J Barber; Wayne J Morgan; Sairam Parthasarathy
Journal:  J Clin Sleep Med       Date:  2018-09-15       Impact factor: 4.062

4.  Implantation of ventricular assist device for systemic right ventricular failure in a patient with transposition of the great arteries and post-Mustard procedure: a case report.

Authors:  Kazutomo Saito; Hiroaki Toyama; Nozomu Abe; Azusa Sunouchi; Yutaka Ejima; Masanori Yamauchi
Journal:  JA Clin Rep       Date:  2018-07-25

5.  Effects of acceptance and commitment therapy on self-management skills and psychological resilience of young and middle-aged patients underwent percutaneous transluminal coronary intervention for primary myocardial infarction: a pilot study.

Authors:  Jiaoyu Cao; Panpan Sun; Lixiang Zhang; Xia Chen; Wenjuan Gui; Anping Ou; Kaibing Chen; Likun Ma
Journal:  Trials       Date:  2022-01-12       Impact factor: 2.279

Review 6.  Current Desensitization Strategies in Heart Transplantation.

Authors:  Marlena V Habal
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.